Anika Therapeutics (ANIK) Non Operating Income (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Non Operating Income data on file, last reported at $667000.0 in Q1 2026.

• On a quarterly basis, Non Operating Income rose 60.72% year-over-year to $667000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 7.59% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 25.37% from the prior year.
• Non Operating Income for Q1 2026 stood at $667000.0, up from $118000.0 in the prior quarter.
• Over the last five years, Non Operating Income for ANIK reached as high as $997000.0 in Q3 2025 and fell as low as -$154000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $453764.7 across 5 years, with a median of $539000.0 in 2023.
• On a YoY basis, Non Operating Income climbed as much as 1008.33% in 2022 and fell as far as 258.14% in 2022.
• Year by year, Non Operating Income stood at $276000.0 in 2022, then soared by 109.06% to $577000.0 in 2023, then grew by 28.94% to $744000.0 in 2024, then slumped by 84.14% to $118000.0 in 2025, then surged by 465.25% to $667000.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $667000.0 in Q1 2026, $118000.0 in Q4 2025, and $997000.0 in Q3 2025.